AR106220A1 - SPECIFIC HOMOGENIC SITE CONNECTORS WITH KSP INHIBITORS - Google Patents

SPECIFIC HOMOGENIC SITE CONNECTORS WITH KSP INHIBITORS

Info

Publication number
AR106220A1
AR106220A1 ARP160101869A ARP160101869A AR106220A1 AR 106220 A1 AR106220 A1 AR 106220A1 AR P160101869 A ARP160101869 A AR P160101869A AR P160101869 A ARP160101869 A AR P160101869A AR 106220 A1 AR106220 A1 AR 106220A1
Authority
AR
Argentina
Prior art keywords
conjugates
specific
homogenic
diseases
ksp inhibitors
Prior art date
Application number
ARP160101869A
Other languages
Spanish (es)
Inventor
Dr Kensch Oliver
Dr Tebbe Jan
Dr Griebenow Nils
Greven Simone
Dr Rebstock Anne
Sophie - Dr Mahlert Christoph
Dr Sommer Anette
Dr Stelte-Ludwig Beatrix
Dr Cancho-Grande Yolanda
Dr Lerchen Hans-Georg
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AR106220A1 publication Critical patent/AR106220A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Conjugados de ligador-fármaco homogéneo específicos de sitio de inhibidores de proteína de huso de quinesina, a metabolitos activos de estos conjugados, a procesos para preparar estos conjugados, al uso de estos conjugados para el tratamiento y/o la prevención de enfermedades y al uso de estos conjugados para preparar medicamentos para el tratamiento y/o la prevención de enfermedades, en particular trastornos hiperproliferativos y/o trastornos angiogénicos tales como, por ejemplo, enfermedades cancerosas. Estos tratamientos se pueden realizar como monoterapia o incluso en combinación con otros medicamentos u otras medidas terapéuticas.Site-specific homogeneous linker-drug conjugates of kinesin spindle protein inhibitors, to active metabolites of these conjugates, to processes to prepare these conjugates, to the use of these conjugates for the treatment and / or prevention of diseases and to the use of these conjugates to prepare medicaments for the treatment and / or prevention of diseases, in particular hyperproliferative disorders and / or angiogenic disorders such as, for example, cancerous diseases. These treatments can be performed as monotherapy or even in combination with other medications or other therapeutic measures.

ARP160101869A 2015-06-23 2016-06-22 SPECIFIC HOMOGENIC SITE CONNECTORS WITH KSP INHIBITORS AR106220A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15173488 2015-06-23

Publications (1)

Publication Number Publication Date
AR106220A1 true AR106220A1 (en) 2017-12-27

Family

ID=53476788

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101869A AR106220A1 (en) 2015-06-23 2016-06-22 SPECIFIC HOMOGENIC SITE CONNECTORS WITH KSP INHIBITORS

Country Status (1)

Country Link
AR (1) AR106220A1 (en)

Similar Documents

Publication Publication Date Title
AR108021A1 (en) ADJUSTMENTS OF ANTIBODY-ACTIVE PRINCIPLE (ADCS) OF KSP INHIBITORS WITH ANTI-B7H3 ANTIBODIES
MX2017017138A (en) Targeted conjugates of ksp inhibitors.
MX2016008013A (en) Antibody drug conjugates (adcs) with kinesin spindel protein (ksp).
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MY188139A (en) Sodium channel modulators for the treatment of pain
BR112017018964A2 (en) use of plinabulin and methods to treat brain tumor
AR096892A1 (en) A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MX2015012322A (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders.
BR112017006113A8 (en) Auristatin uses, pharmaceutical compositions, dosage forms for cancer treatment and kits.
CO7101244A2 (en) Substituted phenylimidazopyrazoles and their use
WO2014153385A3 (en) Methods of treating metabolic disorders
BR112018002530A2 (en) combinations and uses and treatments of these
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
UY36202A (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES RECOMBINANT HEMOGLOBIN OR A THERAPEUTIC AGENT BASED ON SUBUNITIES FOR CANCER TREATMENT
EA201501164A1 (en) SOLID PHARMACEUTICAL MEDICINE FORM
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12018500450A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
MX2018004112A (en) Rational combination therapy for the treatment of cancer.
CO2018004803A2 (en) Oxa-diazaspiro compounds that have activity against pain
AR106220A1 (en) SPECIFIC HOMOGENIC SITE CONNECTORS WITH KSP INHIBITORS
AR097179A1 (en) TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND FLUPIRTINE
BR112019023944A2 (en) pharmaceutical combination for the treatment of cancer
MX2018008196A (en) Treatment of breast cancer using a combination of a cationic liposomal formulation of taxane, a non-liposomal formulation of taxane and a further active agent.

Legal Events

Date Code Title Description
FB Suspension of granting procedure